naringin | 29838-68-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: naringin
• 英文别名: naringenin 7-O-neohesperidoside；7-rhamnoglucosyl-4',5-dihydroxyflavanone；7-[[2-O-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-4h-1-benzopyran-4-one；7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
• CAS: 29838-68-4
• 化学式: C₂₇H₃₂O₁₄
• 分子量: 580.543
• InChiKey: DFPMSGMNTNDNHN-JJLSSNRUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  41
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  225
• 氢给体数：
  8
• 氢受体数：
  14

反应信息

• 作为反应物：
  描述：

  naringin 在 吡啶 、 硫酸 、 碘 作用下， 以 水 为溶剂， 反应 26.0h， 生成 德国春黄菊油
  参考文献：
  名称：

  Site-Selective Synthesis of Acacetin and Genkwanin through Lipase-Catalyzed Deacetylation of Apigenin 5,7-Diacetate and Subsequent Methylation

  摘要：

  DOI：

  10.3987/com-18-s(f)17
• 作为产物：
  描述：

  4'-rhamnoglucosyloxy-2',4,6'-trihydroxychalcone 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 生成 naringin
  参考文献：
  名称：

  Gonzalez, Evangelina A.; Nazareno, Monica A.; Borsarelli, Claudio D., Journal of the Chemical Society. Perkin Transactions 2 (2001), 2002, # 12, p. 2052 - 2056

  摘要：

  DOI：

文献信息

• [EN] ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS<br/>[FR] FLAVONOÏDES CONTENANT DE L'ALCYNE, DE L'AZIDE ET DU TRIAZOLE UTILISÉS COMME MODULATEURS DE RÉSISTANCE MULTIPLE AUX MÉDICAMENTS DANS LES CANCERS
  申请人：UNIV HONG KONG POLYTECHNIC

  公开号：WO2013127361A1

  公开（公告）日：2013-09-06

  A triazole bridged flavonoid dimer compound library was efficiently constructed via the cycloaddition reaction of a series of flavonoid-containing azides (Az 1-15) and alkynes (Ac 1-17). These triazole bridged flavonoid dimers and their precursor alkyne- and azide-continaing flavonoids were screened for their ability to modulate multidrug resistance (MDR) in P-gp-overexpressed cell line (LCC6MDR), MRPl-overexpressed cell line (2008/MRPl) and BCRP-overexpressed cell line (HEK293/R2 and MCF7-MX100). Generally, they displayed very promising MDR reversal activity against P-gp-, MRPl- and BCRP-mediated drug resistance. Moreover, they showed different levels of selectivity for various transporters. Overall, they can be divided into mono-selective, dual-selective and multi-selective modulators for the P-gp, MRPl and BCRP transporters. The EC50 values for reversing paclitaxel resistance (141 - 340 nM) of LCC6MDR cells, DOX (78 - 590 nM) and vincristine (82 - 550 nM) resistance of 2008/MRPl cells and topotecan resistance (0.9 - 135 nM) of HEK293/R2 and MCF7-MX100 cells were at nanomolar range. Importantly, a number of compounds displayed EC50 at or below 10 nM in BCRP-overexpressed cell lines, indicating that these bivalent triazoles more selectively inhibit BCRP transporter than the P-gp and MRPl transporters. Most of the dimers are notably safe MDR chemosensitizers as indicated by their high therapeutic index values.

  通过对一系列含有三唑基的黄酮类化合物（Az 1-15）和炔烃（Ac 1-17）进行环加成反应，高效构建了一个三唑桥联的黄酮二聚体化合物库。对这些三唑桥联的黄酮二聚体及其前体炔烃和三唑基的黄酮类化合物进行了筛选，以评估它们对P-gp过表达细胞系（LCC6MDR）、MRP1过表达细胞系（2008/MRP1）和BCRP过表达细胞系（HEK293/R2和MCF7-MX100）调节多药耐药性（MDR）的能力。总体而言，它们显示出对P-gp、MRP1和BCRP介导的药物耐药性具有非常有前景的MDR逆转活性。此外，它们对各种转运蛋白显示出不同程度的选择性。总体而言，它们可以分为对P-gp、MRP1和BCRP转运蛋白具有单选择性、双选择性和多选择性调节剂。逆转LCC6MDR细胞对紫杉醇耐药性（141-340 nM）、2008/MRP1细胞对阿霉素（78-590 nM）和长春碱（82-550 nM）耐药性以及HEK293/R2和MCF7-MX100细胞对托泊替康耐药性（0.9-135 nM）的EC50值在纳摩尔范围内。重要的是，许多化合物在BCRP过表达的细胞系中显示出EC50在或低于10 nM，表明这些双价三唑更具选择性地抑制BCRP转运蛋白而不是P-gp和MRP1转运蛋白。大多数二聚体根据其高治疗指数值显示出明显安全的MDR化疗敏感化剂特性。
• METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER
  申请人：TACHDJIAN Catherine

  公开号：US20120041078A1

  公开（公告）日：2012-02-16

  The present invention includes methods of stabilizing one or more sweet enhancers when they are exposed to a light source as well as liquid compositions containing one or more sweet enhancers and one or more photostabilizers.

  本发明包括在甜味增强剂暴露于光源时稳定一个或多个甜味增强剂的方法，以及包含一个或多个甜味增强剂和一个或多个光稳定剂的液体组合物。
• AhR mediators
  申请人：Krutmann Jean

  公开号：US20090028804A1

  公开（公告）日：2009-01-29

  The invention relates to a method for finding and assessing agonists [and] antagonists of the aryl hydrocarbon receptor (Ah receptor; AhR), to the agonists and antagonists themselves and to uses thereof.

  这项发明涉及一种用于寻找和评估芳香族羟基化合物受体（Ah受体；AhR）的激动剂和拮抗剂的方法，以及这些激动剂和拮抗剂本身及其用途。
• [EN] COCRYSTALS OF TRIGONELLINE<br/>[FR] CO-CRISTAUX DE TRIGONELLINE
  申请人：CRYSTALMORPHIX TECH PVT LTD

  公开号：WO2017001991A1

  公开（公告）日：2017-01-05

  The present invention relates to new crystalline compounds containing Trigoneline and a cocrystal former. More particularly the present invention relates to Trigonelline cocrystals, therapeutic uses of the Trigoneline cocrystals and pharmaceutical compositions containing them. The cocrystal formers of the present invention include ascorbic acid, L-arginine, aspirin, caffeine, caffeic acid, carnitine, Chlorogenic acid, chrysin, creatine, coumaric acid, curcumin, EGCG, ferulic acid, gallic acid, genistein, glucosamine HCl, 4-hydroxybenzoic acid, 4-hydroxyisoleucine, ibuprofen, lipoic acid, luteolin, melatonin, MSM, naproxen, naringenin, naringin, nicotinamide, nicotinic aicd, paracetamol, protocatecuic acid, L-proline, Quercetin, rutin, resveratrol.

  本发明涉及包含 trigoneline（ trigonelline，即 trigonella）和共晶形成剂的新结晶化合物。更具体地说，本发明涉及 trigonelline 共晶、trigonelline 共晶的治疗用途以及包含它们的药物组合物。本发明的共晶形成剂包括抗坏血酸、L-精氨酸、阿司匹林、咖啡因、咖啡酸、肉碱、绿原酸、白杨素、肌酸、香豆酸、姜黄素、表没食子儿茶素没食子酸酯（EGCG）、阿魏酸、没食子酸、染料木素、盐酸氨基葡萄糖、4-羟基苯甲酸、4-羟基异亮氨酸、布洛芬、硫辛酸、木犀草素、褪黑素、甲基磺酰甲烷（MSM）、萘普生、柚皮素、柚皮苷、烟酰胺、烟酸、对乙酰氨基酚、原儿茶酸、L-脯氨酸、槲皮素、芦丁、白藜芦醇。
• BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF
  申请人：SENOMYX, INC.

  公开号：US20160376263A1

  公开（公告）日：2016-12-29

  The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.

  本发明涵盖已知用于改变苦味感知的化合物和组合物，以及所述组合物和化合物与额外的组合物、化合物和产品的组合。示例组合物包括以下一种或多种：冷却剂；无活性药物成分；活性药用成分；食品添加剂或食品；调味剂或调味增强剂；食品或饮料产品；苦味化合物；甜味剂；苦味剂；酸味调味剂；咸味调味剂；鲜味调味剂；植物或动物产品；已知用于宠物护理产品中的化合物；已知用于个人护理产品中的化合物；已知用于家用产品中的化合物；制药制剂；局部制剂；大麻衍生或与大麻相关的产品；已知用于口腔护理产品中的化合物；饮料；香味、香水或除臭剂；已知用于消费品中的化合物；硅化合物；磨料；表面活性剂；发热剂；吸烟物品；脂肪、油脂或乳化剂；和/或益生菌或补充剂。